Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients

LingLong Peng; Rong Wang; JingKun Shang; YongFu Xiong; ZhongXue Fu

doi:10.18632/oncotarget.14801

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients

LingLong Peng, Rong Wang, JingKun Shang, YongFu Xiong and ZhongXue Fu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:15057-15070. https://doi.org/10.18632/oncotarget.14801

Metrics: PDF 1640 views | HTML 2155 views | ?

Abstract

LingLong Peng1,*, Rong Wang1,*, JingKun Shang1, YongFu Xiong1, ZhongXue Fu1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400014, China

*These authors contributed equally to this work

Correspondence to:

ZhongXue Fu, email: [email protected]

Keywords: colorectal cancer, peroxiredoxin 2, antioxidant enzyme, prognosis

Received: November 14, 2016 Accepted: January 10, 2017 Published: January 24, 2017

ABSTRACT

The present study was to investigate the clinical significance of peroxiredoxin 2 (PRDX2), an oncoenzyme, in the development and progression of colorectal cancer(CRC).We found levels of PRDX2 mRNA and protein were higher in CRC cell lines than in normal human colonic epithelial cells. PRDX2 expression was significantly up-regulated in CRC lesions compared with that in the adjacent noncancerous tissues. CRC tissues from 148 of 226 (65.5%) patients revealed high level of PRDX2 protein expression in contrast to only 13 of 226 (5.8%) PRDX2 strong staining cases in the adjacent noncancerous tissues. Increased expression of PRDX2 protein was significantly associated with poor tumor differentiation (p = 0.001), advanced local invasion (p = 0.046), increased lymph node metastasis (p = 0.008), and advanced TNM stage (p = 0.020). Patients with higher PRDX2 expression had a significantly shorter disease-free survival and worse disease-specific survival than those with low expression. Importantly, PRDX2 up-regulation was an independent prognostic indicator for stage I–III, early stage (stage I-II) and advanced stage (stage III) patients. In conclusion, our findings suggest PRDX2 up-regulation correlates with tumor progression and could serve as a useful marker for the prognosis of CRC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14801

Publication Alerts

Research Papers:

Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients

Abstract